



Financial Tear Sheet

Corporate Profile

Global Blood Therapeutics, Inc. (GBT) is a clinical-stage biopharmaceutical dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. GBT is developing its lead product candidate, GBT440, for the treatment of sickle cell disease and idiopathic pulmonary fibrosis.

Primary IR Contact

Myesha Lacy

Phone: 650-351-4730

E-mail: investor@gbt.com

Stock Performance

GBT (Common Stock)

Exchange NASDAQ GS (US Dollar)

Price **\$38.48**

Change (%) ▲ 0.67 (1.77%)

Volume 1,555,314

52 Week Low \$29.96

Market Cap \$1,968,135,046

Rolling EPS -3.25

PE Ratio 0

Shares Outstanding 52,053,294

Data as of 10/22/18 4:00 p.m. ET



Recent Headlines & Events

10/04/18

[GBT Announces New Employment Inducement Grants](#)

10/04/18

[GBT Announces Upcoming Presentations at National Sickle Cell Disease Association of America \(SCDAA\) Convention](#)

09/26/18

[GBT Announces Participation at the 2018 Cantor Global Healthcare Conference](#)

There are currently no events scheduled.

SEC Filings

Filing Date	Form
09/06/18	<u>4</u>
08/30/18	<u>8-K</u>
08/23/18	<u>8-K</u>
08/20/18	<u>4</u>

Corporate Governance

[Ted W. Love, M.D.](#) Chief Executive Officer

[Jeffrey Farrow](#) Chief Financial Officer

[Jung E. Choi](#) Chief Business and Strategy Officer

[Tricia Suvari](#) Chief Legal Officer

[Hing Sham, Ph.D.](#) Senior Vice President, Research

[Peter Radovich](#) Vice President, Program Leadership and Business Strategy

Data provided by Nasdaq. Minimum 15 minutes delayed.